• Publications
  • Influence
The CXCL8-CXCR1/2 pathways in cancer
  • Q. Liu, A. Li, +6 authors K. Wu
  • Medicine, Biology
  • Cytokine & growth factor reviews
  • 25 August 2016
Persistent infection or chronic inflammation contributes significantly to tumourigenesis and tumour progression. C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctionalExpand
  • 174
  • 12
Chimeric antigen receptor T cells: a novel therapy for solid tumors
  • S. Yu, A. Li, +4 authors K. Wu
  • Medicine
  • Journal of Hematology & Oncology
  • 29 March 2017
The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interactingExpand
  • 144
  • 8
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induceExpand
  • 54
  • 4
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by severalExpand
  • 35
  • 2
Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment
Immunotolerance is one of the hallmarks of malignant tumors. Tumor cells escape from host immune surveillance through various mechanisms resulting in tumor progression and therapeutic resistance.Expand
  • 22
  • 2
Recent advances of bispecific antibodies in solid tumors
  • S. Yu, A. Li, +6 authors K. Wu
  • Medicine
  • Journal of Hematology & Oncology
  • 20 September 2017
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attractingExpand
  • 55
  • 1
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
  • S. Yu, Qian Liu, +4 authors K. Wu
  • Medicine
  • Experimental Hematology & Oncology
  • 28 November 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecificExpand
  • 26
  • 1
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
During tumor progression, a subset of cancer cells escape from immune surveillance and eventually develop into measurable tumor mass. Cancer immunotherapy eradicates tumor cells by enhancing multipleExpand
  • 36
  • 1
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
  • Qian Liu, A. Li, +5 authors K. Wu
  • Medicine, Biology
  • Journal of Hematology & Oncology
  • 10 April 2018
BackgroundC-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrineExpand
  • 20
  • 1
The role of cancer-derived microRNAs in cancer immune escape
During malignant transformation, accumulated somatic mutations endow cancer cells with increased invasiveness and immunogenicity. Under selective pressure, these highly immunogenic cancer cellsExpand
  • 8
  • 1